Skip to content
Screener
PBL

Parabilis Medicines

PBLS

Parabilis Medicines is a biotechnology company in the healthcare sector trading on XNAS, led by CEO Mathai Mammen, with a market cap of $3.8B.

Market cap
$3.75B+3.7%
Revenue$2.1M—
Net income-$44.5M—
Free cash flow-$41.7M—
EPS (diluted)-$0.36—
Quarterly · Q3 2026 · change vs. Q3 2025

Earnings

Next report

Feb 11, 2027 (in 3 months)
Revenue estimate$1.1M
EPS estimate-$0.42

Financials

Q3 2026

Income statement

See full
Revenue$2.1M—
Operating income-$54.7M—
Net income-$44.5M—
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$521.2M—
Total debt$41.1M—
Total equity$1.0B—
Total assets$1.1B—

Cash flow

See full
Operating cash flow-$41.1M—
CapEx$611.0K—
Free cash flow-$41.7M—

Valuation & ratios

Valuation

See full
Market cap$3.75B+3.7%
Enterprise value$3.27B—

Returns & leverage

See full
Debt / equity0×—
Current ratio12.9×—

Profile

Listed2026
CEOMathai Mammen
FilingsSEC EDGAR

FAQ

What is Parabilis Medicines's market cap?
Parabilis Medicines (PBLS) has a market capitalization of $3.8B and trades on XNAS.
Where is Parabilis Medicines headquartered?
Parabilis Medicines is headquartered in United States of America. It has been publicly traded since 2026.